Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases.

Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ.

Gastroenterology. 2019 Jun 19. pii: S0016-5085(19)41020-2. doi: 10.1053/j.gastro.2019.06.018. [Epub ahead of print]

PMID:
31228441
2.

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S.

J Crohns Colitis. 2019 Jun 3. pii: jjz110. doi: 10.1093/ecco-jcc/jjz110. [Epub ahead of print]

PMID:
31158271
3.

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.

Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG.

Clin Gastroenterol Hepatol. 2019 May 8. pii: S1542-3565(19)30491-4. doi: 10.1016/j.cgh.2019.04.059. [Epub ahead of print]

PMID:
31077827
4.

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.

Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS.

Inflamm Bowel Dis. 2019 May 3. pii: izz071. doi: 10.1093/ibd/izz071. [Epub ahead of print]

PMID:
31050734
5.

Novel Non-biologic Targets for Inflammatory Bowel Disease.

Shukla T, Sands BE.

Curr Gastroenterol Rep. 2019 Apr 23;21(5):22. doi: 10.1007/s11894-019-0689-2. Review.

PMID:
31016396
6.

Response to Chapman and Jones.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 May;114(5):828. doi: 10.14309/ajg.0000000000000217. No abstract available.

PMID:
30985301
7.

Response to Ribaldone.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 May;114(5):826-827. doi: 10.14309/ajg.0000000000000216. No abstract available.

PMID:
30985300
8.

Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort.

Perler B, Ungaro R, Baird G, Mallette M, Bright R, Shah S, Shapiro J, Sands BE.

BMC Gastroenterol. 2019 Apr 2;19(1):47. doi: 10.1186/s12876-019-0963-7.

9.

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR.

J Crohns Colitis. 2019 Feb 14. pii: jjz038. doi: 10.1093/ecco-jcc/jjz038. [Epub ahead of print]

PMID:
30879034
10.

Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease.

Shmidt E, Suárez-Fariñas M, Mallette M, Moniz H, Bright R, Shah SA, Merrick M, Shapiro J, Xu F, Saha S, Sands BE.

Inflamm Bowel Dis. 2019 Mar 11. pii: izy401. doi: 10.1093/ibd/izy401. [Epub ahead of print]

PMID:
30861068
11.

Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.

Hirten RP, Grinspan A, Fu SC, Luo Y, Suarez-Farinas M, Rowland J, Contijoch EJ, Mogno I, Yang N, Luong T, Labrias PR, Peter I, Cho JH, Sands BE, Colombel JF, Faith JJ, Clemente JC.

Inflamm Bowel Dis. 2019 May 4;25(6):969-979. doi: 10.1093/ibd/izy398.

PMID:
30852592
12.

A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease.

Shmidt E, Suárez-Fariñas M, Mallette M, Moniz H, Bright R, Shah SA, Merrick M, Shapiro J, Xu F, Sands B, Saha S.

Inflamm Bowel Dis. 2019 Jun 18;25(7):1262-1270. doi: 10.1093/ibd/izy397.

PMID:
30726913
13.

Gut microbiota density influences host physiology and is shaped by host and microbial factors.

Contijoch EJ, Britton GJ, Yang C, Mogno I, Li Z, Ng R, Llewellyn SR, Hira S, Johnson C, Rabinowitz KM, Barkan R, Dotan I, Hirten RP, Fu SC, Luo Y, Yang N, Luong T, Labrias PR, Lira S, Peter I, Grinspan A, Clemente JC, Kosoy R, Kim-Schulze S, Qin X, Castillo A, Hurley A, Atreja A, Rogers J, Fasihuddin F, Saliaj M, Nolan A, Reyes-Mercedes P, Rodriguez C, Aly S, Santa-Cruz K, Peters L, Suárez-Fariñas M, Huang R, Hao K, Zhu J, Zhang B, Losic B, Irizar H, Song WM, Di Narzo A, Wang W, Cohen BL, DiMaio C, Greenwald D, Itzkowitz S, Lucas A, Marion J, Maser E, Ungaro R, Naymagon S, Novak J, Shah B, Ullman T, Rubin P, George J, Legnani P, Telesco SE, Friedman JR, Brodmerkel C, Plevy S, Cho JH, Colombel JF, Schadt EE, Argmann C, Dubinsky M, Kasarskis A, Sands B, Faith JJ.

Elife. 2019 Jan 22;8. pii: e40553. doi: 10.7554/eLife.40553.

14.

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice.

Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, Li Z, Mortha A, Merad M, Das A, Gevers D, McGovern DPB, Singh N, Braun J, Jacobs JP, Clemente JC, Grinspan A, Sands BE, Colombel JF, Dubinsky MC, Faith JJ.

Immunity. 2019 Jan 15;50(1):212-224.e4. doi: 10.1016/j.immuni.2018.12.015.

15.

Response to Chamberlin and Borody.

Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 Jan;114(1):171-174. doi: 10.14309/ajg.0000000000000077. No abstract available.

PMID:
30633034
16.

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R.

Clin Gastroenterol Hepatol. 2019 Jan 6. pii: S1542-3565(19)30013-8. doi: 10.1016/j.cgh.2018.12.040. [Epub ahead of print]

17.

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T.

Inflamm Bowel Dis. 2019 Jan 4. doi: 10.1093/ibd/izy384. [Epub ahead of print]

PMID:
30615117
18.

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23.

19.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. No abstract available.

20.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4.

21.

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.

Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T.

Inflamm Bowel Dis. 2019 Mar 14;25(4):803-810. doi: 10.1093/ibd/izy304.

22.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2. doi: 10.1016/j.cgh.2018.09.035. Epub 2018 Sep 27.

23.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation.

Gastroenterology. 2018 Oct;155(4):1098-1108.e9. doi: 10.1053/j.gastro.2018.06.046. Epub 2018 Jun 30.

PMID:
29964043
24.

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, Kaplan GG, Burisch J, Colombel JF.

Gastroenterology. 2018 Oct;155(4):1079-1089.e3. doi: 10.1053/j.gastro.2018.06.043. Epub 2018 Jun 27.

PMID:
29958857
25.

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Sep;113(9):1345. doi: 10.1038/s41395-018-0162-0. Epub 2018 Jun 27. Erratum in: Am J Gastroenterol. 2018 Dec;113(12):1912.

PMID:
29946178
26.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group.

J Crohns Colitis. 2018 Nov 9;12(10):1158-1169. doi: 10.1093/ecco-jcc/jjy085.

PMID:
29917064
27.

Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Jul;113(7):1101. doi: 10.1038/s41395-018-0120-x.

PMID:
29895986
28.

Climate variability differentially impacts thermal fitness traits in three coprophagic beetle species.

Nyamukondiwa C, Chidawanyika F, Machekano H, Mutamiswa R, Sands B, Mgidiswa N, Wall R.

PLoS One. 2018 Jun 6;13(6):e0198610. doi: 10.1371/journal.pone.0198610. eCollection 2018.

29.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 Sep;155(3):687-695.e10. doi: 10.1053/j.gastro.2018.05.039. Epub 2018 May 30.

30.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

31.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2461-2467. doi: 10.1093/ibd/izy171.

PMID:
29788240
32.

The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.

Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG.

J Crohns Colitis. 2018 Jul 30;12(8):883-895. doi: 10.1093/ecco-jcc/jjy055.

PMID:
29726939
33.

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1101.

PMID:
29610508
34.

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.

Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.

Gastroenterology. 2018 Jul;155(1):76-87. doi: 10.1053/j.gastro.2018.03.032. Epub 2018 Mar 28. Review.

PMID:
29601825
35.

Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease.

Zhang X, Ko HM, Torres J, Panchal HJ, Cai Z, Wagner M, Sands BE, Colombel JF, Cho J, Taouli B, Harpaz N.

Hum Pathol. 2018 Sep;79:42-49. doi: 10.1016/j.humpath.2018.03.004. Epub 2018 Mar 16.

PMID:
29555578
36.

Environmental consequences of deltamethrin residues in cattle feces in an African agricultural landscape.

Sands B, Mgidiswa N, Nyamukondiwa C, Wall R.

Ecol Evol. 2018 Feb 14;8(5):2938-2946. doi: 10.1002/ece3.3896. eCollection 2018 Mar.

37.

Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients.

Rebello D, Anjelly D, Grand DJ, Machan JT, Beland MD, Furman MS, Shapiro J, LeLeiko N, Sands BE, Mallette M, Bright R, Moniz H, Merrick M, Shah SA.

Osteoporos Int. 2018 Jun;29(6):1359-1366. doi: 10.1007/s00198-018-4444-6. Epub 2018 Mar 8.

PMID:
29520605
38.

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC.

Inflamm Bowel Dis. 2018 Feb 15;24(3):651-659. doi: 10.1093/ibd/izx039.

PMID:
29462380
39.

What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?

Long MD, Sands BE.

Clin Gastroenterol Hepatol. 2018 May;16(5):618-620. doi: 10.1016/j.cgh.2018.02.010. Epub 2018 Feb 15. No abstract available.

PMID:
29454043
40.

When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?

Long MD, Sands BE.

Clin Gastroenterol Hepatol. 2018 May;16(5):621-623. doi: 10.1016/j.cgh.2018.02.011. Epub 2018 Feb 14. No abstract available.

PMID:
29454042
41.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.

J Crohns Colitis. 2018 Mar 28;12(4):510. doi: 10.1093/ecco-jcc/jjx168. No abstract available.

PMID:
29385425
42.

Clinical experience and two-year follow-up with a one-piece viscoelastic cervical total disc replacement.

Chin KR, Lubinski JR, Zimmers KB, Sands BE, Pencle F.

J Spine Surg. 2017 Dec;3(4):630-640. doi: 10.21037/jss.2017.12.03.

43.

Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists.

Nulsen B, Sands BE, Shah BJ, Ungaro RC.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):155-160. doi: 10.1097/MEG.0000000000001010.

PMID:
29240002
44.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2018 Mar 28;12(4):408-418. doi: 10.1093/ecco-jcc/jjx161.

PMID:
29216349
45.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133. Erratum in: J Crohns Colitis. 2019 Jan 1;13(1):139-140.

46.

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.

Feagan BG, Sands BE, Rossiter G, Li X, Usiskin K, Zhan X, Colombel JF.

Gastroenterology. 2018 Jan;154(1):61-64.e6. doi: 10.1053/j.gastro.2017.08.035. Epub 2017 Aug 25.

47.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

48.

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.

Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.

49.

Developmental screening in children with CHD: Ages and Stages Questionnaires.

Noeder MM, Logan BA, Struemph KL, Condon N, Mueller I, Sands B, Davies RR, Sood E.

Cardiol Young. 2017 Oct;27(8):1447-1454. doi: 10.1017/S1047951117000415. Epub 2017 Apr 5.

50.

The Whys and Hows of Fourth-Year Inflammatory Bowel Disease Fellowships.

Hirten R, Sands BE, Cohen BL.

Dig Dis Sci. 2017 May;62(5):1116-1118. doi: 10.1007/s10620-017-4555-5. No abstract available.

PMID:
28365918

Supplemental Content

Support Center